Dr. Vanessa Zann: Pharmaceutical Technology Contribution
Dr. Vanessa Zann, Senior Drug Development Consultant at Quotient Sciences featured in Pharmaceutical Technology looking at the important role of early-phase biopharmaceutics.
Quotient Sciences Contributes to Clinical Pharmacology in Drug Development article, "A Phase 1 Study of Savolitinib"
Quotient Sciences experts contribute to a recent article in the American College of Clinical Pharmacology® Clinical Pharmacology in Drug Development journal that highlights the results of an ADME study of AstraZeneca's savolitinib.
Quotient Sciences Wins Multiple Categories in 2023 CDMO Leadership Awards
Quotient Sciences is a multi-category award winner of the 2023 CDMO Leadership Awards. Now in its 12th year, the CDMO Leadership Awards recognizes superior performance by contract development and manufacturing organizations (CDMO's) across multiple categories, as voted by customers.
Quotient Sciences Expands Formulation Development Capabilities at Nottingham, UK
An expansion of our early-phase formulation development capabilities for oral dosage forms at our Nottingham, UK, facility builds upon our existing formulation capabilities.
Stuart McDougall: European Bioanalysis Forum Workshop Contribution
Stuart McDougall, Quotient Sciences' Principal Research Fellow of Bioanalytical Services, contributes to the European Bioanalysis Forum Workshop on the Harmonized Implementation of the ICH M10 Guideline.